TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34499038
Drug: Digital rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rehabilitation therapy using a biofeedback device provided by SWORD Health, performed independently at home.
Study: 34499416
Drug: Merestinib 80
Normalized name: Mereletinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Merestinib 80 mg orally QD during a 28-day cycle
Study: 34499416
Drug: Merestinib 120
Normalized name: Mereletinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Merestinib 120 mg orally QD during a 28-day cycle
Study: 34499416
Drug: Merestinib 80
Normalized name: Mereletinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Merestinib 80 mg orally QD with cisplatin 25 mg/m2
Study: 34499613
Drug: Web-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive behavioral therapy, mindfulness meditation, and yoga (CBT-MY)
Study: 34499720
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefazolin IV infusion
Study: 34499720
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefazolin IV infusion (administered if delivery delayed >8 h)
Study: 34499720
Drug: Standard pre-delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pre-delivery maternal cefazolin dosing
Study: 34503455
Drug: Propofol continuous
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol continuous infusion with a stepwise increase of 1 μg/mL in effect-site concentration (C)
Study: 34503957
Drug: Glucagonlike peptide-1
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagonlike peptide-1 receptor (GLP1R) imaging using PET radioligand
Study: 34504096
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel and bevacizumab chemotherapy
Study: 34504096
Drug: CTCs and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTCs and ctDNA levels at baseline and after four weeks of treatment
Study: 34504096
Drug: CTC count
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CTC count at four weeks (≥5CTC/7.5 mL)
Study: 34505132
Drug: Tuberculosis Preventive
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculosis Preventive Therapy
Study: 34505172
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose (RD) protocol, volumetric CT dose index (CTDIvol) 3.04 mGy, 64-slice unit
Study: 34505172
Drug: Ultra-low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low dose (ULD) protocol, median CTDIvol 0.38 mGy, dual-source unit
Study: 34506875
Drug: Fluid bolus
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid bolus of 500 ml plasma-lyte A
Study: 34507560
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with a stoma
Study: 34507560
Drug: No stoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: No stoma treatment
Study: 34507574
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl 12 mcg/h
Study: 34507574
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine 10 mg b.i.d.
Study: 34509409
Drug: Patient-worn accelerometers
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-worn accelerometers measuring Physical Average Daily Activity (PADA)
Study: 34509409
Drug: Patient-worn accelerometers
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-worn accelerometers measuring Total Average Daily Activity
Study: 34510123
Drug: Potential genetic
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential genetic targets for SSNHL treatments
Study: 34510485
Drug: Frequent antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent antibiotic courses
Study: 34511132
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy (n = 67)
Study: 34511975
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of plasma PTX3 levels and PR
Study: 34513679
Drug: CD-19 CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD-19 CAR-T immunotherapy (second generation CAR containing CD28 or 4-1BB therapy)
Study: 34513681
Drug: Biodegradable rectal
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biodegradable rectal spacer balloon
Study: 34514436
Drug: SARS-CoV-2 mRNA
Normalized name: SARS-CoV-2 mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 mRNA vaccines (Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273)
Study: 34515215
Drug: HKT288 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HKT288 (0.3 mg/kg IV every 3 weeks)
Study: 34515215
Drug: HKT288 (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: HKT288 (0.75 mg/kg cohort)
Study: 34515215
Drug: HKT288 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HKT288 (0.3 mg/kg IV)
Study: 34516954
Drug: Tisagenlecleucel (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisagenlecleucel (target dose 5 × 10^5 CAR T cells)
Study: 34518090
Drug: Hyperuricemic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperuricemic group (SUA > 7 mg/dl in men, > 6 mg/dl in women)
Study: 34518162
Drug: Anti-VEGF therapy
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF therapy initiation during lockdown (16 March 2020 through 31 July 2020)
Study: 34518162
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (sham-control arm data from Minimally Classic/Occult Trial)
Study: 34519109
Drug: High PPI
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High PPI dose (≥ 20 OE/day)
Study: 34519839
Drug: anti-CD47 antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-CD47 antibodies
Study: 34519839
Drug: anti-CD47 antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-CD47 antibodies + IFN-α
Study: 34520127
Drug: Fluzone® Quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzone® Quadrivalent (IIV4) vaccine
Study: 34520638
Drug: Systemic antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antidepressant treatments
Study: 34520638
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic antidepressant treatments
Study: 34521113
Drug: mAb CAEL-101
Normalized name: Caelyx
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mAb CAEL-101 (11-1F4) administered as a single intravenous infusion with escalating doses from 0.5 mg/m2 to 500 mg/m2 in phase 1a and as 4 weekly infusions in phase 1b.
Study: 34523045
Drug: Management according
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management according to ophthalmic and systemic disease
Study: 34524220
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon α-2b (HD-IFN)
Study: 34524647
Drug: Procalcitonin <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin < 0.1 ng/mL
Study: 34525286
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg vaccine
Study: 34525286
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg vaccine
Study: 34525286
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg and 2 mg vaccines
Study: 34526044
Drug: Sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (200 mg d1, every 3 weeks, until disease progression, unacceptable toxicity, or up to 35 cycles) + SBRT (8 Gy × 3) + GM-CSF (125 μg/m)
Study: 34526151
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavior Therapy (G-CBT) for 3 months
Study: 34526151
Drug: Individual Outpatient
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Outpatient Treatment (IOT) for 3 months
Study: 34526151
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavior Therapy (G-CBT)
Study: 34526151
Drug: Individual Outpatient
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Outpatient Treatment (IOT)
Study: 34526343
Drug: Monthly self-report
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly self-report of falls (including number and severity) confirmed through interviews
Study: 34526804
Drug: iota-carrageenan containing
Normalized name: iota-Carrageenan
DrugBank: iota-Carrageenan (DB15304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iota-carrageenan containing lozenge
Study: 34527608
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (sorafenib followed by yttrium 90 glass microspheres)
Study: 34528591
Drug: MPFF +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF + compression + topical treatment
Study: 34528591
Drug: MPFF +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF + compression + topical treatment + endovasal laser coagulation
Study: 34528591
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving topical treatment
Study: 34528591
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not receiving compression therapy
Study: 34528591
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving compression therapy
Study: 34528763
Drug: Poziotinib 12
Normalized name: Poziotinib
DrugBank: Poziotinib (DB12114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poziotinib 12 mg orally once daily for 28-day cycle
Study: 34529182
Drug: Inhaled prostacyclin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled prostacyclin analogues
Study: 34529182
Drug: Inhaled epoprostenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled epoprostenol (VPCOVID [NCT04452669])
Study: 34529226
Drug: No antirheumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antirheumatic drug intake
Study: 34529255
Drug: Antibiotics initiated
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antibiotics initiated for presumed bacterial respiratory tract co-/superinfection
Study: 34529255
Drug: Drivers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drivers of antibiotic prescribing
Study: 34529762
Drug: AZD1222 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1222 vaccine (1 dose)
Study: 34529930
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiotherapy (SABR) with dosing of 54 Gy in three fractions for peripheral lesions or 50 Gy in four fractions for central tumours (totaling 60 Gy).
Study: 34529930
Drug: Video-assisted thoracoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND)
Study: 34529983
Drug: Cockcroft-Gault creatinine
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cockcroft-Gault creatinine clearance (C-G)
Study: 34530728
Drug: Psychotropic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic drug prescriptions (PTDs)
Study: 34530728
Drug: Antipsychotic prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic prescriptions
Study: 34530728
Drug: Sedatives/hypnotics prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedatives/hypnotics prescriptions
Study: 34530733
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment initiation
Study: 34530744
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for COVID-19 patients
Study: 34530760
Drug: Pyrotinib 400
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib 400 mg once daily and thalidomide 200 mg once daily until disease progression or intolerable toxicity
Study: 34530760
Drug: Pyrotinib 400
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib 400 mg once daily and thalidomide 200 mg once daily
Study: 34530793
Drug: Internal fixation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal fixation treatment for lower limb fractures
Study: 34531249
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg on day 1 and carboplatin AUC 2 on days 8 and 15 of a 3-week cycle until progression
Study: 34531250
Drug: CD33-directed chimeric
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD33-directed chimeric antigen receptor T cell immunotherapy (CD33CARTs) with CD28 costimulatory domain
Study: 34531250
Drug: CD33-directed chimeric
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD33-directed chimeric antigen receptor T cell immunotherapy (CD33CARTs) with 4-1BB costimulatory domain
Study: 34531279
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose potassium treatment
Study: 34531279
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose potassium treatment
Study: 34531443
Drug: Collar Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collar Therapy Indicator (COTI) for monitoring radioactive iodine uptake
Study: 34531588
Drug: Chimeric antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor (CAR) T-cells
Study: 34531755
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) treatment, specific dosage and duration not available
Study: 34533472
Drug: SARS-CoV-2 antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 antibodies measured in saliva
Study: 34533772
Drug: No inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No inhalation technique errors
Study: 34533772
Drug: Inhalation technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation technique errors
Study: 34533772
Drug: Adhering to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhering to medication
Study: 34533772
Drug: Not adhering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not adhering to medication
Study: 34533772
Drug: PIF measurements,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIF measurements, inhalation technique, medication adherence
Study: 34534421
Drug: Long-Acting Injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-Acting Injectable Antipsychotic Medication plus Customized Adherence Enhancement
Study: 34534430
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (6.4 mg per kilogram of body weight)
Study: 34535360
Drug: Initial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial insulin therapy for ≥3 months
Study: 34536405
Drug: Onasemnogene abeparvovec
Normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Onasemnogene abeparvovec gene therapy (1·1×10^14 vg/kg) administered as a one-time intravenous infusion.
Study: 34539356
Drug: CT38s at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT38s at an infusion rate of 0.03 μg/kg/h
Study: 34540013
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy plus apatinib (250 mg/day for 28 days)
Study: 34540651
Drug: Molecular profiling
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular profiling for tailoring adjuvant therapy in the high-intermediate-risk group
Study: 34540697
Drug: Low-dose apatinib
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose apatinib combined with S-1
Study: 34540703
Drug: Low-dose craniospinal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose craniospinal irradiation (18 Gy)
Study: 34540919
Drug: Aspirin for
Normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin for primary prevention of cardiovascular disease
Study: 34541429
Drug: Surgery or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery or medical treatments for diverticular disease
Study: 34541429
Drug: Medical treatments,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatments, interventional radiology, and surgery
Study: 34542729
Drug: Arterial stiffness
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterial stiffness measures (pulse wave velocity, augmentation index) and HRV indices
Study: 34543383
Drug: Uproleselan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uproleselan (10 mg/kg twice daily) plus MEC (mitoxantrone, etoposide, and cytarabine)
Study: 34543383
Drug: Uproleselan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uproleselan (10 mg/kg twice daily) plus cytarabine and idarubicin (7 + 3)
Study: 34543383
Drug: Uproleselan added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uproleselan added to chemotherapy
Study: 34543477
Drug: Chemotherapy (platinum-based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (platinum-based, four to six cycles)
Study: 34544269
Drug: Dual compartment
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual compartment suppositories
Study: 34544430
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal challenge (50 g fat)
Study: 34548050
Drug: Concurrent wasting-stunting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent wasting-stunting
Study: 34548321
Drug: LY3200882 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3200882 monotherapy
Study: 34548321
Drug: LY3200882 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3200882 in combination therapy
Study: 34548324
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition administered in the first 7 days of postnatal life
Study: 34550085
Drug: Microbial Ecosystem
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbial Ecosystem Therapeutic (MET)-2, daily orally administered capsule containing 40 bacterial strains for 6 weeks
Study: 34550633
Drug: TOP2 poison
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOP2 poison chemotherapy
Study: 34551725
Drug: Veterans Administration
Normalized name: benzalkonium chloride Topical Foam [Veteran Shield 24]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veterans Administration Video Connect (VVC)
Study: 34551886
Drug: Venetoclax (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (400 mg daily for days 1 to 28), Pomalidomide (daily for days 1 to 21), Dexamethasone (weekly for each 28-day cycle)
Study: 34551886
Drug: Venetoclax (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (400 mg daily for days 1 to 28)
Study: 34551940
Drug: Maternal vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal vitamin B exposure (exact dosage and duration not specified)
Study: 34552007
Drug: Epigenetic inhibitors,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epigenetic inhibitors, specific agents not mentioned, duration not specified.
Study: 34552007
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors, specific agents not mentioned, duration not specified.
Study: 34552864
Drug: ACY-241 (citarinostat)
Normalized name: Citarinostat
DrugBank: Citarinostat (DB15449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACY-241 (citarinostat) at 180 mg
Study: 34552864
Drug: ACY-241 (citarinostat)
Normalized name: Citarinostat
DrugBank: Citarinostat (DB15449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACY-241 (citarinostat) at 360 mg
Study: 34552864
Drug: ACY-241 (citarinostat)
Normalized name: Citarinostat
DrugBank: Citarinostat (DB15449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACY-241 (citarinostat) at 480 mg
Study: 34552864
Drug: Nivolumab at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab at 240 mg
Study: 34552937
Drug: Ayurvedic Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic Nutritional Therapy